INFOS !

NEW ADDRESS: The management team of ERN-EYE is moving! Starting from March 19, you can find us at 1 Rue Eugène Boeckel, 67000 Strasbourg.

Accessibility and reading comfort

Text size

Light/Dark mode

Lines vertical spacing

Accessibility

More about accessibility

Trouble using our website?
Contact us

Safety Study of RPE65 Gene Therapy to Treat Leber Congenital Amaurosis

Clinical Trial

NCT00643747 Completed

Safety Study of RPE65 Gene Therapy to Treat Leber Congenital Amaurosis

Safety Study of RPE65 Gene Therapy to Treat Leber Congenital Amaurosis

Phase 1/2

Interventional

Disease

Disease type

Leber Congenital Amaurosis

Orphan drug recognition

NA

Inclusion / Exclusion

Opening date

01/01/2007

Closing date

01/12/2014

Inclusion criteria :

Exclusion criteria :

Funding

industry

Members involved

Others investigators

Dr Axel PETZOLD

Netherlands

Neuro-Ophthalmology Rare Diseases (WG2), Research (TWG8)